Everest Medicines announces ambitious 2030 growth strategy as leadership raises stakes

CHINA— Everest Medicines has announced its comprehensive 2030 strategy, prompting immediate investor enthusiasm that drove the company’s shares upward during trading.

The stock climbed to an intraday high of HKD 48.54 (USD 6.23) before settling at HKD 46.88 (USD 6.02) by market close, representing a 4.55% gain for the session.

Market observers attributed the strong performance to two key factors: investor interest in the company’s newly articulated medium- to long-term vision and confidence signals from its leadership team.

Just days before the strategy announcement, several directors and a major shareholder demonstrated their commitment by purchasing additional shares in the company.

On December 12, 2025, four senior leaders collectively acquired 846,659 ordinary shares through open-market transactions.

Wei Fu, Non-executive Director and Honorary Chairman of the Board, joined forces with Yifang Wu, Executive Director and Chairman, Rogers Yongqing Luo, Executive Director and Chief Executive Officer, and Ian Ying Woo, Executive Director, President and Chief Financial Officer, to complete purchases totaling more than HK$38 million (USD4.9 million).

The transactions reflected an average price of approximately HK$45.01 (USD5.78) per share.

Adding to this vote of confidence, CBC Group, a substantial shareholder of the company, announced plans to increase its stake by up to 1% over the following three to six months, subject to market conditions and regulatory compliance.

These moves signal strong belief in the company’s trajectory from those closest to its operations.

The 2030 strategy outlines a dual-engine approach designed to balance immediate and future growth.

Everest Medicines plans to deliver predictable near-term value through commercializing existing assets, forming business development partnerships, and achieving in-house research and development milestones.

Simultaneously, the company aims to drive long-term growth through internal R&D and discovery efforts alongside global commercial expansion.

The biopharmaceutical company focuses on five core therapeutic areas: renal, autoimmune, critical care, cardiovascular, and ophthalmic diseases.

Everest Medicines advances its pipeline through a combination of in-licensed innovative assets and proprietary research.

By 2030, the company intends to build a high-value commercial product portfolio while selectively expanding into additional therapeutic areas with blockbuster potential.

Currently, Everest Medicines markets three commercial products and continues developing a fully integrated commercial platform covering the entire product lifecycle.

The company has set ambitious financial targets, aiming to exceed RMB 15 billion (USD 2.06 billion) in annual revenue by 2030.

This figure includes approximately RMB 9 billion (USD 1.24 billion) from its existing pipeline and RMB 6 billion (USD 824 million) from newly in-licensed assets.

The company projects revenue will grow at a compound annual growth rate exceeding 50% from 2025 to 2030, with sustained growth above 15% thereafter.

The commercial product portfolio is expected to expand significantly, with more than 20 products in the market by 2030.

Key assets include NEFECON®, Velsipity®, XERAVA®, cefepime–taniborbactam, and Lerodalcibep.

To support international expansion, Everest Medicines strengthens its regulatory and clinical development capabilities while progressively building commercial infrastructure across Europe, the United States, and emerging markets.

The company holds approximately 16% of NovaBridge Biosciences’ issued share capital and plans to collaborate with this partner to identify high-quality assets and enhance global R&D and commercialization capabilities through shared strengths and resources.

Wei Fu emphasized that the strategy reflects clear vision across commercialization, R&D, and global expansion.

He noted that CBC Group will continue leveraging its global resources and ecosystem to support the company’s growth across pipeline advancement, platform building, and organizational expansion.

Yifang Wu highlighted that the company plans to add three to five late-stage, high-value assets annually through its business development capabilities and the CBC ecosystem.

These new assets target peak sales within three years of reimbursement and are expected to contribute around RMB 6 billion (USD 824 million) by 2030 and RMB 30 billion (USD 4.12 billion) by 2035.

Rogers Yongqing Luo pointed to the company’s scalable commercialization platform, which integrates medical, access, marketing, and sales capabilities.

NEFECON®, a chronic disease therapy, generated over RMB 1 billion (USD 137 million) in sales during the first three quarters following its commercial launch, validating the company’s commercial effectiveness.

The company plans to extend its commercial model from renal and anti-infective therapies to additional therapeutic areas while advancing its in vivo mRNA CAR-T and mRNA tumor vaccine platforms to address unmet medical needs in China and globally.